TRP Event Series

With early-stage biotechs seeing a notable rise in seed funding, we’re excited to announce the addition of a dedicated Investor Panel to the 7th Targeted Radiopharmaceuticals Summit Europe. This session offers a valuable opportunity to hear directly from leading venture and strategic investors, as well as experienced biotech companies, including, Cellectar Biosciences, Inc., Brookline Capital Markets, and Seroba. They will discuss what they are prioritizing in radiopharmaceutical innovation and how companies can best position themselves for meaningful growth. Key discussion points will include: - Differences between the US and European investment landscapes - Key considerations and investor expectations unique to the European market - Actionable insights on securing funding from those actively investing in the space View the full session agenda here: https://ter.li/sqvmxm 𝐒𝐞𝐜𝐮𝐫𝐞 𝐲𝐨𝐮𝐫 𝐩𝐥𝐚𝐜𝐞 𝐛𝐲 𝐅𝐫𝐢𝐝𝐚𝐲, 𝟏𝟖 𝐉𝐮𝐥𝐲 𝐚𝐧𝐝 𝐬𝐚𝐯𝐞 𝐮𝐩 𝐭𝐨 €𝟗𝟎𝟎 𝐨𝐧 𝐲𝐨𝐮𝐫 𝐫𝐞𝐠𝐢𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧. #Radiopharmaceuticals #Biotech #LifeSciences #InvestorPanel #BiotechFunding #TRPSummit

Just 2 weeks to go! The 4th Targeted Radiopharmaceuticals Summit US hits San Diego, July 29–31. Join 250+ TRP leaders across discovery, development & supply at the largest US event focused on TRP innovation. Recently confirmed attendees: TheraPaint, Tailor Therapeutics, Alpha-9 Oncology, Sanofi, RayzeBio & more. Check out the latest agenda here: https://ter.li/asn7ox Want the updated delegate list? Drop us a message or comment below. #Radiopharmaceuticals #TRP #Oncology #DrugDevelopment #BiotechEvents #SanDiego

Just 4 weeks left until the 4th Targeted Radiopharmaceuticals Summit US! Excitement is building with recent registrations from leading industry players including AdvanCell Isotopes, Johnson & Johnson Innovative Medicine, and Eli Lilly. Don’t miss the opportunity to hear from 50+ expert speakers across 3 days of cutting-edge, data-driven content! Engage in 11+ hours of curated networking with key stakeholders from across the field, including Novartis, AstraZeneca, BMS, Ratio Therapeutics, Alpha-9 Oncology, Mariana Oncology, Abdera Therapeutics, and a range of innovative startups and CDMOs. Be part of the community driving forward precision radiopharmaceuticals to transform patient care. Learn more here: https://ter.li/m6p5ur

We’re excited to announce the launch of the 𝟕𝐭𝐡 𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐑𝐚𝐝𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 𝐒𝐮𝐦𝐦𝐢𝐭 𝐄𝐮𝐫𝐨𝐩𝐞, taking place 10–12 November in Amsterdam. As the leading annual meeting for the RLT community, this event brings together experts across discovery, clinical development, manufacturing and regulatory affairs to accelerate the next generation of targeted radiopharmaceuticals. 𝐖𝐡𝐚𝐭’𝐬 𝐧𝐞𝐰 𝐢𝐧 𝟐𝟎𝟐𝟓: - 45+ expert speakers, including voices from Bayer, Novartis, AstraZeneca and more - A brand-new third track: Discovery & Preclinical, Translational & Clinical, and CMC & Sourcing - Six focused workshops on dosimetry, drug design and more The all-new event guide is now live, explore the full agenda and speaker line-up. View the programme here: https://ter.li/gkndmo #TRSEurope2025 #Radiopharmaceuticals #RLT #Biotech #DrugDevelopment #NuclearMedicine #PharmaInnovation

𝐖𝐞𝐫𝐞 𝐲𝐨𝐮 𝐚𝐭 𝐒𝐍𝐌𝐌𝐈 𝐭𝐡𝐢𝐬 𝐲𝐞𝐚𝐫? The energy around readouts and headlines was electric - but it also highlighted a simple truth: radiopharma still has a long road ahead. That’s why the 𝟒𝐭𝐡 𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐑𝐚𝐝𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 𝐒𝐮𝐦𝐦𝐢𝐭 ��𝐒 is so timely. As the only industry-led event focused on isotope supply, clinical development, regulatory clarity, and novel target selection, it’s where real progress happens. 𝐃𝐨𝐧’𝐭 𝐦𝐢𝐬𝐬: 𝐔𝐬𝐢𝐧𝐠 𝐏𝐚𝐭𝐢𝐞𝐧𝐭-𝐂𝐞𝐧𝐭𝐫𝐢𝐜 𝐏𝐡𝐚𝐬𝐞 𝐙𝐞𝐫𝐨 𝐓𝐫𝐢𝐚𝐥𝐬 𝐟𝐨𝐫 𝐑𝐚𝐝𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 8:30 AM | Workshop A With experts from Alpha-9 Oncology, RayzeBio, and AdvanCell, this session explores how Phase 0 studies bridge preclinical and clinical development, with a focus on ethics, global compassionate use, and patient safety. 𝘛𝘩𝘪𝘴 𝘪𝘴 𝘺𝘰𝘶𝘳 𝘧𝘪𝘯𝘢𝘭 𝘸𝘦𝘦𝘬 𝘵𝘰 𝘴𝘢𝘷𝘦 𝘶𝘱 𝘵𝘰 $300 𝘰𝘯 𝘺𝘰𝘶𝘳 𝘱𝘢𝘴𝘴. 🔗 Explore the lineup: https://ter.li/xfd21p 🔗 Register now: https://ter.li/c54n64

We're thrilled to welcome Mirion Medical as the newest partner joining us at the 4th Targeted Radiopharmaceuticals Summit US! They join an impressive lineup of industry leaders, including: PSI, BioLogic Pharma Solutions, ITM, Stream Realty Partners, TerThera, Lantheus, PepLib, PharmaLogic, Flywheel, SHINE, Trasis, AtomVie, IONETIX, Isotopia, Macrocyclics, PeptiFinder, Perceptive, LigandTracer, 48Hour Discovery, and NorthStar Medical Radioisotopes. With just a few weeks left before partnership opportunities close, now’s the time to get involved. These partners play a critical role in advancing radiopharmaceutical development by streamlining workflows through targeted services and solutions. Interested? View the program (https://ter.li/h6j07v) or connect with Mehmet Gul, BSc, our Partnership Director, to explore opportunities.

Dive into next-gen targeted therapies at the 4th Targeted Radiopharmaceuticals Summit US pre-conference workshop day! Workshop B: Antibodies & Pre-targeting • Lessons from Zevalin & Bexxar • Advanced click-linker & radiolabeling • Matching isotope & biological half-lives • Smarter pre-targeting strategies Workshop C: Peptides, Mini-Proteins & Membrane Targets • New membrane-bound targets • Engineering peptides & mini-proteins • Reducing kidney toxicity • Optimizing biodistribution Plus, sessions across the full R&D spectrum and a fundamentals day for newcomers or those needing a refresher. View the workshop sessions in more detail here: https://ter.li/kkyh2a PS: If you register your place by this Friday, you can save up to $500. #Radiopharmaceuticals #TargetedTherapies #DrugDevelopment #Biotech #TRPUS2025 #OncologyResearch #MedicalInnovation

𝐑𝐚𝐝𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐝𝐫𝐮𝐠 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐜𝐨𝐧𝐭𝐢𝐧𝐮𝐞𝐬 𝐭𝐨 𝐜𝐥𝐚𝐢𝐦 𝐢𝐭𝐬 𝐰𝐞𝐥𝐥-𝐝𝐞𝐬𝐞𝐫𝐯𝐞𝐝 𝐬𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭 𝐢𝐧 𝐰𝐞𝐞𝐤𝐥𝐲 𝐡𝐞𝐚𝐝𝐥𝐢𝐧𝐞𝐬. 𝐁𝐮𝐭 𝐰𝐡𝐚𝐭 𝐝𝐨 𝐭𝐡𝐞𝐬𝐞 𝐡𝐞𝐚𝐝𝐥𝐢𝐧𝐞𝐬 𝐫𝐞𝐚𝐥𝐥𝐲 𝐬𝐢𝐠𝐧𝐚𝐥 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐟𝐢𝐞𝐥𝐝? 𝐄𝐚𝐫𝐥𝐲-𝐒𝐭𝐚𝐠𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭 Lantheus and Eli Lilly’s discontinuation of their Phase III PSMA-targeting radiotherapeutic due to insufficient efficacy reinforces the growing view that, while PSMA remains relevant, the field must now look beyond it. Now more than ever, drug developers are turning toward novel targets and next-generation targeting moieties. 𝐋𝐚𝐭𝐞-𝐒𝐭𝐚𝐠𝐞 𝐌𝐨𝐦𝐞𝐧𝐭𝐮𝐦 Recent investments from Ratio Therapeutics and BMS, including BMS’s $40B U.S. commitment, highlight a clear pivot. Radiopharma is evolving from clinical exploration to commercial readiness. The spotlight now shifts to scalable manufacturing, regulatory alignment, and real-world deployment. 𝐇𝐨𝐰 𝐜𝐚𝐧 𝐭𝐡𝐞 𝟒𝐭𝐡 𝐓𝐑𝐏 𝐔𝐒 𝐒𝐮𝐦𝐦𝐢𝐭 𝐡𝐞𝐥𝐩? Gain strategic insights from leading experts on topics such as: • Moving Beyond PSMA: Novel targets with UCSF, PepLib and Actinium • Mining for Gold: Discovering blockbuster targets with UPenn and Transcenta • Expanding Horizons: Advancing novel moieties with Telix and OncoOne 𝐏𝐥𝐮𝐬, 𝐞𝐬𝐬𝐞𝐧𝐭𝐢𝐚𝐥 𝐥𝐚𝐭𝐞-𝐬𝐭𝐚𝐠𝐞 𝐬𝐞𝐬𝐬𝐢𝐨𝐧𝐬: • Strengthening CMC and Supply Chain with Abdera, Clarity and PharmaLogic • Clinical Learnings for Late-Stage Development with UCLA, TRASIS and SHINE • Supply Optimization with Novartis, RayzeBio and others Whether your focus is on Discovery and Preclinical, Translational and Early Clinical, or Supply Chain and Late Stage Clinical, the 4th Targeted Radiopharmaceuticals Summit US is where you’ll stay ahead of the curve. 𝘝𝘪𝘦𝘸 𝘵𝘩𝘦 𝘰𝘧𝘧𝘪𝘤𝘪𝘢𝘭 𝘱𝘳𝘰𝘨𝘳𝘢𝘮 𝘩𝘦𝘳𝘦: 𝘩𝘵���𝘱𝘴://𝘵𝘦𝘳.𝘭𝘪/6𝘦𝘢𝘰3𝘹 #Radiopharma #DrugDevelopment #Oncology #TRP2025 #LifeSciences #SupplyChain #ClinicalDevelopment #Biotech #PharmaInnovation

Our next Summit will take place in San Diego this July. Looking forward to meeting you all!